OBJECTIVES: The overall goal of our project is to adapt an Austrian decision-analytic model for the treatment of chronic myeloid leukemia (CML) to the U.S. context. We conducted an electronic survey to gain expert knowledge about the state-of-the-art in CML treatment. METHODS: The expert survey was constructed as an online questionnaire and contained 14 questions. The questionnaire was developed in collaboration with ONCOTYROL project partners and distributed to CML experts at the Huntsman Cancer Institute in Utah. Data were generated using Qualtrics and discussed with experts in order to incorporate the findings into the model. RESULTS: Four out of six experts (67%) stated that effectiveness of second-line TKI depends on the response to first-line TKI therapy. NCCN and ELN guidelines are the most frequently used guidelines when treating CML patients. Furthermore, expert opinion, literature and personal characteristics influence decision making. Patients younger than 50, or between 50 and 54 years, most frequently receive stem cell transplantation after TKI failure. The recently approved TKIs bosutinib and ponatinib are used by 17% and 100% respectively. Experts stated that quality of life (QoL) on dasatinib is better (17%)/ about the same (50%)/ worse (33%) compared to imatinib. QoL on nilotinib is better (17%)/ about the same (83%) in comparison to imatinib. QoL on ponatinib is better (17%)/ about the same (67%)/ worse (17%) compared to imatinib. Although bosutinib is rarely (67%) used, experts answered that is better (17%) or about the same (17%) compared to imatinib. CONCLUSIONS: The results provide valuable insights into the state-of-the-art of CML treatment in the U.S. context. Due to the small sample size and the limitation to the region of Utah, results should be interpreted carefully. However, the responses for ponatinib and bosutinib are particularly valuable for the model due to lack of QoL and long-term data.